Efficacy of berberine in patients with type 2 diabetes mellitus

source extracted confidence: high 2026-04-09
#adult #aged #berberine #cholesterol-hdl #diabetes-mellitus-type-2

Efficacy of berberine in patients with type 2 diabetes mellitus

Yin et al., 2008 | Metabolism | Rct

Citation

Yin Jun, Xing Huili, Ye Jianping. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008-May;57(5):712-7. doi:10.1016/j.metabol.2008.01.013

Abstract

Berberine has been shown to regulate glucose and lipid metabolism in vitro and in vivo. This pilot study was to determine the efficacy and safety of berberine in the treatment of type 2 diabetes mellitus patients. In study A, 36 adults with newly diagnosed type 2 diabetes mellitus were randomly assigned to treatment with berberine or metformin (0.5 g 3 times a day) in a 3-month trial. The hypoglycemic effect of berberine was similar to that of metformin. Significant decreases in hemoglobin A1c (from 9.5%+/-0.5% to 7.5%+/-0.4%, P<.01), fasting blood glucose (from 10.6+/-0.9 mmol/L to 6.9+/-0.5 mmol/L, P<.01), postprandial blood glucose (from 19.8+/-1.7 to 11.1+/-0.9 mmol/L, P<.01), and plasma triglycerides (from 1.13+/-0.13 to 0.89+/-0.03 mmol/L, P<.05) were observed in the berberine group. In study B, 48 adults with poorly controlled type 2 diabetes mellitus were treated supplemented with berberine in a 3-month trial. Berberine acted by lowering fasting blood glucose and postprandial blood glucose from 1 week to the end of the trial. Hemoglobin A1c decreased from 8.1%+/-0.2% to 7.3%+/-0.3% (P<.001). Fasting plasma insulin and homeostasis model assessment of insulin resistance index were reduced by 28.1% and 44.7% (P<.001), respectively. Total cholesterol and low-density lipoprotein cholesterol were decreased significantly as well. During the trial, 20 (34.5%) patients experienced transient gastrointestinal adverse effects. Functional liver or kidney damages were not observed for all patients. In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.

Key Findings

In conclusion, this pilot study indicates that berberine is a potent oral hypoglycemic agent with beneficial effects on lipid metabolism.

Outcomes Measured

  • Requires manual extraction

Population

Field Value
Population See abstract
Sample Size 36
Age Range See abstract
Condition diabetes

MeSH Terms

  • Adult
  • Aged
  • Berberine
  • Cholesterol, HDL
  • Diabetes Mellitus, Type 2
  • Drug Therapy, Combination
  • Female
  • Glucose
  • Glycated Hemoglobin
  • Humans
  • Male
  • Metformin
  • Middle Aged

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
  • Vertical: berberine

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09